Investor AB to accept Agnafit Bidco’s public offer for the shares in Swedish Orphan Biovitrum AB

Investor AB to accept Agnafit Bidco’s public offer for the shares in Swedish Orphan Biovitrum AB

(PRESS RELEASE) STOCKHOLM, 2-Sep-2021 — /EuropaWire/ — Investor AB (STO: INVE-B), a Swedish investment and holding company founded in 1916, has announced its support for the Agnafit Bidco¹’s bid for Sobi (Swedish Orphan Biovitrum AB). The company has undertaken to accept today’s public offer by Agnafit Bidco for the shares in Swedish Orphan Biovitrum AB (publ) (Sobi) at a price per share of SEK 235. Presently Investor owns 107.6 million shares in Sobi, which represents 35.4 percent of the capital and votes. The offer values Investor’s shares in Sobi at SEK 25.3bn, corresponding to 21x the invested amount, or an IRR of 28 percent.

In 2010, Investor was instrumental in the creation of Sobi as the lead shareholder of its predecessors Swedish Orphan International (SOI) and Biovitrum.

During Investor’s ownership, Sobi has successfully built a leading hemophilia franchise greatly benefitting patients. In addition, the company has with our support broadened its product portfolio within Hematology and Immunology, organically and through major acquisitions. This has created significant value for Sobi’s and Investor’s shareholders. Sobi’s Board of Directors has recommended Sobi’s shareholders to accept the offer. We believe that the offer is financially attractive. Advent International, the lead investor in Agnafit Bidco, has a well-proven track record of healthcare investments.

Assuming completion of the offer, Investor’s financial position will be further strengthened. We intend to utilize this strength by continuing to invest in existing and new platform companies within Patricia Industries, selectively invest within Listed Companies as well as in EQT funds”, says Investor’s President and CEO Johan Forssell.

Investor’s undertaking to accept the offer will lapse under certain circumstances, including if a third party makes a competing offer for Sobi at a price per share of SEK 251 or more and such offer is unanimously recommended by the Sobi board. Full details are provided in Agnafit Bidco’s offer announcement press release today.

Assuming that the offer is declared unconditional, the transaction is expected to be completed in the fourth quarter 2021. Completion of the offer is conditional upon, among other things, the receipt by Agnafit Bidco of all necessary regulatory approvals and that the offer is accepted to such an extent that Agnafit Bidco becomes the owner of more than 90 percent of the shares in Sobi.

¹Agnafit Bidco AB is indirectly owned by Advent International Corporation and Aurora Investments Pte Ltd, a nominated investment vehicle of GIC Special Investments Pte Ltd, which is a subsidiary of GIC Pte Ltd.

Investor, founded by the Wallenberg family in 1916, is an engaged owner of high quality global companies. We have a long-term investment perspective. Through board participation, as well as industrial experience, our network and financial strength, we work continuously to support our companies to remain or become best-in-class. Our holdings include, among others, ABB, Atlas Copco, Ericsson, Mölnlycke and SEB.

Media contacts:

Viveka Hirdman-Ryrberg, Head of Corporate Communication and Sustainability,
Phone +46 70 550 3500
viveka.hirdman-ryrberg@investorab.com

Magnus Dalhammar, Head of Investor Relations,
Phone +46 73 524 2130
magnus.dalhammar@investorab.com

SOURCE:  Investor AB

MORE ON INVESTOR AB, HEMATOLOGY, ETC.:

Follow EuropaWire on Google News
EDITOR'S PICK:

Comments are closed.